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A B S T R A C T   
Molecular medical imaging is intended to increase the accuracy of diagnosis, particularly in cardiovascular and 
cancer-related diseases, where early detection could significantly increase the treatment success rate. In this 
study, we present mixed micelles formed from four building blocks as a magnetic resonance imaging targeted 
contrast agent for the detection of atheroma and cancer cells. The building blocks are a gadolinium-loaded DOTA 
ring responsible for contrast enhancement, a fibrin-specific CREKA pentapeptide responsible for targeting, a 
fluorescent dye and DSPE-PEG2000. The micelles were fully characterized in terms of their size, zeta potential, 
stability, relaxivity and toxicity. Target binding assays performed on fibrin clots were quantified by fluorescence 
and image signal intensities and proved the binding power. An additional internalization assay showed that the 
micelles were also designed to specifically enter into cancer cells. Overall, these multimodal mixed micelles 
represent a potential formulation for MRI molecular imaging of atheroma and cancer cells.   
1. Introduction 
Cardiovascular disease and cancer are the primary causes of human 
death worldwide [1]. Early diagnosis therefore plays a key role in the 
successful treatment and increased survival rate of both diseases. Med-
ical imaging techniques such as magnetic resonance imaging (MRI), 
computed tomography, positron emission tomography or ultrasound are 
commonly used for the detection and diagnosis of these diseases. 
To further improve the diagnostic quality and interpretability of the 
images, continuous improvements are made on devices and software, on 
one hand [2], and, on the other hand, research towards the synthesis of 
new target-specific contrast agents (CAs) and tracers for molecular im-
aging is conducted [3,4]. 
MRI is a noninvasive diagnostic procedure that allows imaging of all 
parts of the human body, especially soft tissues [5]. To overcome the low 
sensitivity of the technique and to highlight different tissues that would 
normally have the same contrast, gadolinium (Gd)-based contrast agents 
(Gd-CA), in which the Gd(III) cation is strongly chelated, are commonly 
injected during MRI scans. They affect the signal by shortening the 
T1-relaxivity time of the proton and thus positively enhance the 
contrast in the tissues where they are located. They are indirect CAs, as 
they are not directly observed on the final image, contrary to contrast 
agents used in other imaging modalities [6]. Research on direct MRI CAs 
has been undertaken but has not yet led to commercial products [7]. 
Gd-CAs can be classified in several ways. First, the structure of the 
chelate can be considered: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tet-
raacetic acid (DOTA) is a macrocyclic ligand with the advantage of being 
extremely stable with no Gd release [8], whereas the linear 
diethylentriaminepenta-acetic acid (DTPA) ligand [9] forms less stable 
complexes. For more than ten years, Gd-DTPA has been associated with 
severe side effects due to the propensity of Gd3+ release from DTPA. This 
may lead to nephrogenic systemic fibrosis (NSF) [10] or Gd brain 
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deposition [11]. Second, Gd-CAs can be classified according to the fate 
of the molecule in the body. On the one hand, Gd-DOTA and 
Gd-DTPA are called extravascular CAs because of their fast clearance 
after injection, mostly by kidneys and partly by the liver [12]. Fortu-
nately, a fraction of the injected dose escapes the vessels and diffuses for 
a short period of time in the tissues of interest, such as brain structures, 
hematomas, tumors, joints and others [6]. On the other hand, blood pool 
contrast agents (BPCAs), such as Gadofosveset [13] and Gd-micelles 
[14,15], remain in the vascular compartment longer and allow imag-
ing of the cardiovascular system even with long MRI sequences [16]. 
Finally, as mentioned above, research is now focused on target-specific 
CAs, which will accumulate mainly in a selected tissue [17] or a specific 
cellular target [18], allowing molecular imaging, which is crucial for 
early and precise diagnosis. 
Above all, MRI CA development faces another issue: new high- 
magnetic-field MRI equipment significantly decreases the relaxivity 
potential of Gd-CAs, requiring the introduction of a higher concentration 
of product to increase the signal [19,20]. The property relaxivity is 
therefore a crucial parameter in Gd-CA development. 
Currently, there is an increased need for high-relaxivity vascular- 
Table 1 
Building blocks and their roles.  
Building block Role Chemical structure 
1 Gd-DO3A-Tyr-(C18)2 Gd-CA 
2 DSPE-PEG2000-CREKA Fibrin binding block 
2bis DSPE-PEG2000-CERAK Fibrin nonbinding control 
3 DSPE-PEG2000-IR-774 Fluorescent block 
4 DSPE-PEG2000 Stabilizing block 
Fig. 1. Mixed micelle formulation by nanoprecipitation.  
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targeted specific BPCAs that will enable molecular imaging for an early 
diagnosis of vascular disease and vascularized tumor tissues. One 
approach is to design supramolecular nanoconstructs having a size that 
impedes excessively fast tissue diffusion and clearance. These materials 
incorporate imaging moieties and targeting moieties and potentially an 
additional drug for theranostic purposes. Such nanoconstructs may be 
nanoparticles, liposomes or micelles [15,21–23]. To date, several pep-
tides and antibodies have been added to MRI supramolecular constructs 
[24–27]. Among others, the Cys-Arg-Glu-Lys-Ala peptide (CREKA) 
showed very encouraging results as a targeting moiety for blood clots 
[18,28]. This pentapeptide binds specifically to fibrin clots that are 
formed during blood coagulation [29]. This can occur either on the 
surface of atheroma plaques or in small leaky vessels of tumors. It is 
therefore a peptide of interest to be incorporated into the structure of 
supramolecular Gd-CAs for molecular imaging. 
Previously, we reported several micelle formulations designed as 
BPCA for MRI [14,15,30,31]. They circulated for a prolonged period of 
time in blood vessels and allowed cardiovascular imaging with high 
resolution. The results obtained in our previous MRI studies led us to 
add a targeting moiety on supramolecular nanoconstructs for molecular 
imaging. 
Therefore, the aim of the present work was to develop a BPCA for 
MRI of atherosclerosis. Here, we report the synthesis of building blocks 
and formulation of a novel mixed-micelle for vascular targeting. Three 
building blocks were synthesized: 
(1) Gd-DO3A-Tyr-(C18)2 for MRI imaging [32], (2) DSPE-PEG2000- 
CREKA for targeting and (3) DSPE-PEG2000-IR-774 for orthogonal 
fluorescence detection and potential cancer cell internalization. DSPE- 
PEG2000 was added for the stabilization of the micelles [33]. Three 
different micelle compositions, varying in proportion of the targeting 
moiety, were tested. The micelles were characterized in terms of their 
size, zeta potential, stability and relaxivity properties. Four different cell 
lines were chosen for in vitro cytotoxicity evaluation and fluorescence 
imaging. The efficiency of MRI was determined by scans on phantoms. 
Finally, fibrin clot binding assays were performed in vitro with either 
fluorescence detection or MRI. 
This research provides an improved way for imaging and diagnosis 
of atherosclerosis and cancer cells detection, the two leading causes of 
human death. Results and findings of this study show the significance 
advancement towards targeted vascular MRI contrast agents. 
2. Materials and methods 
2.1. Synthesis of micelle building blocks 
Building blocks were synthesized according to published procedures 
[14,15,34–36]. 
The synthetic details and Gd3+ loading of the chelates are reported in 
the Supplementary Information. The micelles were formulated with four 
building blocks (Table 1). DSPE-PEG2000 was purchased from Sigma- 
Aldrich (Buchs, Switzerland), and the other three blocks, Gd-DO3A- 
Tyr-(C18)2, DSPE-PEG2000-CREKA and 
DSPE-PEG2000-IR-774, were synthesized. Additionally, DSPE- 
PEG2000-CERAK was synthesized as a scrambled negative control for 
binding assays. 
2.2. Micelle preparation 
Micelles were prepared by nanoprecipitation [14,15,30,31] (Fig. 1). 
Briefly, building blocks were dissolved in an organic mixture of acetone 
and ethanol (50/50 v/v) and added dropwise to ultrapure water under 
magnetic stirring. After 1 min, the organic phase was completely 
evaporated under reduced pressure over approximately 15 min, result-
ing in a stable and homogeneous aqueous micellar solution. 
Three formulations with variable proportions of building blocks 
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each targeted formulation, a nontargeting (negative) control formula-
tion was prepared by adding DSPE-PEG2000-CERAK – a nontargeting 
peptide analog of CREKA. 
2.3. Micelle characterization 
Micelles were characterized by dynamic light scattering (DLS) in 
terms of their size, stability and zeta potential and by transmission 
electron microscopy (TEM). For these experiments, the targeted and 
control micelles were prepared at 1 mM (sum of the different compo-
nents). The hydrodynamic diameter of the micelles was assessed by DLS, 
as described previously [15]. A NANO ZS ZEN 3600 instrument from 
Malvern (Malvern, Worcestershire, United Kingdom) controlled by 
ZetaSizer 7.01 software was used for particle size and zeta potential 
measurements. The analyses were performed with a 4 mW He–Ne laser 
(633 nm) at a scattering angle of 173◦ at 25 ◦C in a polystyrene semi- 
micro cuvette (VWR, Nyon, Switzerland). The refractive index was 
1.590, and the material absorption was 0.010. 
2.4. Stability 
The stability of the micelles was assessed at T = 25 ◦C for 10 days. 
First, a visual inspection was performed after 7 days to evaluate aggre-
gation, and then DLS measurements were carried out after 10 days if no 
aggregation was observed to confirm the visual analysis. 
2.5. Transmission electron microscopy (TEM) 
Mixes 1, 2 and 3 were imaged with an FEI TECNAI® G2 Sphera TEM 
equipped with a TCL camera (Gräfelfing, Germany). First, the samples 
were negatively stained with 2 % uranyl on carbon film 200-mesh 
copper grids. The samples were observed at 120 kV. The carbon grids 
were pretreated under plasma for 20 s at 0.3 Torr and 400 V. 
2.6. Gadolinium (Gd) quantification 
For comparison purposes and the accuracy of relaxivity calculations, 
the Gd-loading of the Gd-DO3A-Tyr-(C18)2 building block and the Gd- 
concentration in Mixes 1, 2 and 3 were precisely determined by induc-
tively coupled plasma coupled to mass spectrometry (ICP-MS; 7800 se-
ries; Agilent, Tokyo, Japan). (Details are reported in the Sup Info.) 
2.7. Nuclear magnetic resonance (NMR) relaxometry 
For relaxivity measurements, mixes were prepared with a fixed 
concentration of Gd3+ of 1.0 mM. Details are reported in the Supple-
mentary Information 
2.8. Absorbance and fluorescence measurements 
Absorbance and fluorescence were performed on the different for-
mulations (mixes) and the fluorescent building block DSPE-PEG2000-IR- 
774 alone (Sup Info Fig. SI1 and SI2). 
Fluorescence binding assay of fibrin clots (Fig. 2) 
The procedure for binding assays was adapted from several reports 
[37–39]. Fig. 2 shows the schematic representation of the assay and 
details are reported in the Supplementary Information. 
Magnetic resonance imaging (MRI) phantom images and binding 
assay 
Similar to the relaxivity measurements, the mixes and anti-mixes 
were prepared with a designated concentration of Gd (1, 0.5, 0.25, 
0.125, 0.05 mM). Then, 200 μL of the formulations were poured into the 
wells of a 96-well plate. Gd-DOTA solutions at the same Gd concentra-
tions were used as controls. Experiments were performed first without 
fibrin in the plates. Second, a binding assay was performed with fibrin 
clots, as described in the previous section (Fig. 2). Standard echo 
gradient 2D MRI was performed using a 3.0 T RS2D Mediso with an 8 cm 
core and equipped with a volume coil (excitation/reception). The MRI 
parameters used were coronal orientation, 
12 slices × 1 mm thickness, FOV = 80 × 40 mm, TE/TR = 3.78/101 
ms, matrix = 256 × 128, flip angle = 75◦, 20 scans averaged, duration =
4 min 35 s. The signal intensity (SI) in the wells was quantified and 
normalized to noise. Regions of interest were drawn on the images using 
Osirix software (©Pixmeo Sarl, OsiriX Open source http://www.osirix-v 
iewer.com). The output gave the mean and standard deviation of the 
signal in each well. 
3. In vitro cell viability experiments 
The cytotoxicity of the micelle formulations and of the building 
blocks alone was evaluated using a standard cell proliferation reagent 
(WST-1, Roche) in four different cell lines purchased from ATCC: 
HUVEC (human umbilical vein endothelial cells), 
EC-RF24 (immortalized human vascular endothelial cells), MCF-7 
(breast cancer cell line), and MCF-10 (nontumorigenic epithelial 
breast cell line). 
Cells were grown according to ATCC guidelines at 37 ◦C in a hu-
midified 5 % CO2 atmosphere in appropriate medium with 10 % (v/v) 
heat-inactivated fetal calf serum (FCS) (Eurobio, France) and penicillin- 
streptomycin (10,000 U/mL) (Gibco by Life Technologies). 
A total of 100 μL of cells was seeded in a 96-well plate at an initial 
density of 5x103 cells/well. After 24 h of incubation (37 ◦C, 5 % CO2), 
the medium was replaced by 100 μL of a solution of mixes and controls 
(building blocks alone and Gd-DOTA (Dotarem®)) at different concen-
trations (0.1, 0.5, 1.0, 2.0, 3.0 mM) for comparison. After 24 h of in-
cubation with the formulations, the medium was replaced by WST-1 
solution according to the manufacturer’s instructions (11644807001, 
Roche, Sigma-Aldrich, St. Gallen, Switzerland). After further incubation 
for 1 h at 37 ◦C in an incubator, the absorbance of the wells at 450 nm 
was read with a plate reader (Synergy 2, Biotek™) with the reference 
wavelength set at 690 nm, and the results were recorded with Gen5 2.00 
Software. The cell viability was calculated as follows:   
The viability tests for each concentration were performed in 
triplicate. 
3.1. Live-cell imaging 
Intracellular localization of the micelles was performed on MCF-7 
and MCF-10 cell lines. The cells were seeded at a concentration of 
15,000 cells/well in a black 96-well plate (ibidi, Germany) for 3 days. 
Culture media were supplemented with 10 % fetal calf serum (Eurobio) 
cell viability (%) = [(Absorbance of treated well) − (Absorbance of ​ nontreated well)]/[(Absorbance of ​ nontreated well)
− (Absorbance of negative control)]*100.
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and 1 % penicillin/streptomycin (Thermo Fisher Scientific). After 3 
days, the cells were washed with PBS and incubated with fluorescent 
micelles at different concentrations of the dye (1, 10, 50, 100 µM) for 30 
min. Mitochondria were then stained with MitoTracker® Green, and 
nuclei were stained with Hoechst® for 15 min. The cells were washed 
with PBS, incubated with Fluorobrite® medium and imaged using an 
IXM-XL microscope (Molecular Devices, 1x40). The images were 
analyzed using MetaXpress software (Molecular Devices). 
3.2. Statistics 
Figures and statistical analysis (2-was ANOVA test) were computed 
using GraphPad Prism 7.02, (GraphPad Software Inc.) software. P- 
values < 0.05 were considered as statistically significant. 
4. Results 
4.1. Synthesis of the building blocks 
As described, the building blocks were synthesized according to 
published procedures [14,15,34–36]. The final global yield of Gd-DO3A- 
Tyr-(C18)2 was 20 %, that of DSPE-PEG2000-CREKA was 82 %, and that of 
DSPE-PEG2000-IR-774 was 43 %. 
4.2. Micelle mixture formulation and characterization tests 
As described, micelles were formed by nanoprecipitation according 
to a published procedure [14,15,30,31]. Three mixes were prepared to 
assess the effects of different compositions on binding ability. Anti-mixes 
were prepared as negative controls in binding assays with a nontargeting 
peptide having a scrambled amino acid sequence. The characterization 
results are reported in Table 2. The pure building blocks were tested as 
well for comparison. The size of the micelles measured by DLS varied 
around 100 nm, as confirmed by TEM images (Fig. 3). The PDI of the 
micelles varied between 0.2 and 0.3, and for pure building blocks, it 
varied between 0.4 and 0.5. The zeta potential was slightly negative. The 
micelles remained stable for >10 days, with no visual precipitation or 
aggregation, which was confirmed by additional DLS measurements. 
4.3. Cell cytotoxicity assay 
Four different cell lines were chosen to test the toxicity of micelle 
mixes and the building blocks alone: two endothelial cell lines (HUVECs 
– human umbilical vein endothelial cells and EC-RF24 – immortalized 
human vascular endothelial cells) and two breast cell lines (MCF-7 – 
breast cancer cell line and MCF-10 – nontumorigenic epithelial breast 
cell line). Fig. 4 reports the results of the viability assays. The highest 
toxicities were observed with the nonformulated single building blocks 
Gd-DO3A-Tyr-(C18)2 and DSPE-PEG2000-IR-774. No significant toxicity, 
with a viability higher than 80 % at all concentrations, was observed for 
the mixes and anti-mixes containing the four blocks and the other two 
building blocks alone. 
4.4. Relaxivity and MRI phantoms 
To precisely calculate the relaxivity and to robustly compare with a 
commercial Gd-CA, the Gd loading of the chelate was first assessed by 
ICP-MS in the Gd-DO3A-Tyr-(C18)2 building block. This loading was 93 
%. The concentration was then adjusted to Gd3+ when preparing the 
various micelle mixes. 
Fig. 5 shows the results of experiments performed with mixes at 
different concentrations of Gd3+. Gd-DOTA was chosen as a commercial 
control. Fig. 5A shows MRI phantom images obtained with a 96-well 
plate. Fig. 5B shows the results of the relaxivity measurements deter-
mined at several magnetic fields. Fig. 5C presents signal intensity 
graphs, in which the values were measured from the 96-well plates 
shown in Fig. 5A. No visual difference was observed in Fig. 5A; however, 
the relaxivity of the mixes was much higher than that of Gd-DOTA 
(Fig. 5B), and in Fig. 5C, the signal intensities of the mixes were 
higher than that of Gd-DOTA. 
4.5. Binding assay to fibrin clots: fluorescence measurements 
The maximum spectrophotometric absorbance of the fluorescent 
building block was at 774 nm (Sup info Fig. SI1). Fluorescence was 
assessed at λex 774 nm and λem 806 nm (Sup Info Fig. SI1 and SI2). Fig. 6 
reports the results of the binding assay on fibrin clots. Fluorescence 
Fig. 3. TEM micrographs of Mix-1, 2 and 3.  
Fig. 2. Binding assay protocol.  
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values were normalized to the dye concentration in each solution. For 
some solutions, overflow was observed at high concentrations; there-
fore, not all the solutions have experimental points up to 3 mM. Before 
washing, the measurements increased linearly, which is consistent with 
the initial dye concentration. After washing, the values for the mixes 
were significantly higher than those for the anti-mixes, as expected, due 
to the selection of the binding peptide. 
Statistical analysis was performed using a 2-way ANOVA test for 
each concentration between each solution. No significant difference is 
observed between mixes and 
“All wells before washing” at c < 1 mM. On the opposite a significant 
difference is observed between mixes and anti-mixes at all tested con-
centrations above 0.125 mM. 
Fig. 4. Cell viability WST-1 assay in four different cell lines after 24 h of incubation: HUVECs – human umbilical vein endothelial cells, EC-RF24 – immortalized 
human vascular endothelial cells, MCF-7 – breast cancer cell line and MCF-10 – nontumorigenic epithelial breast cell line. 
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4.6. Binding assay to fibrin clots: MR imaging 
A binding assay was also performed by MRI in 96-well plates with 
fibrin-coated wells. For this experiment, the molecular concentration of 
building blocks in the micelles was adjusted to that of Gd3+. Fig. 7A 
shows the MRI of the phantom with images of the plates before and after 
washing. Fig. 7B presents the signal intensities on the phantoms. A 
steady increase in the signal as a function of Gd3+ concentration was 
observed in all wells before washing. After plate washing, the signal 
intensities of the targeted mixes were in all cases higher than those of the 
anti-mixes. In the case of Gd-DOTA, the signal was very low. This was 
expected, as this complex cannot bind to fibrin. 
Statistical analysis was performed using a 2-way ANOVA test for 
each concentration between each solution. No significant difference is 
observed between solutions at c < 0.25 mM. Further, a significant dif-
ference is observed between “All wells before washing”, mixes and anti- 
mixes starting from c = 0.25 mM, and as well between anti-mixes and 
Gd-DOTA starting from c = 0.5 mM. 
4.7. Cell fluorescence imaging 
Cell internalization and fluorescence imaging were performed on 
MCF-7 and MCF-10 cells. Tests were performed on mixes and anti-mixes. 
Images of selected cells for Mix-1 and Anti-Mix-1 are presented in Fig. 8; 
the images of the other mixes and anti-mixes and the resulting fluores-
cence graph are in the Supplementary Information (Fig. SI4 and SI5). 
Fig. 5. A - MRI Phantoms. B - Relaxivity measurements. C - Signal intensity of MRI phantom wells.  
Fig. 6. Binding assay on fibrin clots: Fluorescence measurements (λex 774 nm, λem 806 nm) before and after 5 washes. *Significant difference (0.05) between mixes 
and anti-mixes. **Significant difference (0.05) between mixes, anti-mixes and “All wells before washing”. 
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Internalization was observed for MCF-7 cells at practically all concen-
trations. In contrast, this was only slightly observed at 50 µM in MCF-10 
cells. 
5. Discussion 
5.1. Micelle formulations 
Micelle formulations were chosen for this study. Micelles bear 
several advantages relative to other types of nanoconstructs. First, they 
are simple to formulate by using the nanoprecipitation technique. Sec-
ond, we have already used this formulation method and proved its 
robustness and repeatability to provide an MRI blood pool contrast 
agent [15,31]. Third, in the present study, the micelles obtained were 
homogeneous with regard to their size in all mixes (Table 2), as 
confirmed on TEM micrographs (Fig. 3). It has been shown that it is 
important to have building blocks with both a hydrophilic and hydro-
phobic tail to obtain a narrow size distribution of the micelles [40,41]. 
Fig. 7. Binding assay on fibrin clots. A – MRI of the wells before and after washing. B – MRI signal intensity of the wells as a function of Gd concentration. 
*Significant difference (0.05) between “All wells before washing”, mixes and anti-mixes. ** Significant difference (0.05) between “All wells before washing”, mixes, 
anti-mixes and Gd-DOTA. 
Fig. 8. Cell fluorescence imaging for Mix-1 and Anti-Mix-1 on MCF-7 and MCF-10 cell lines (scale bar = 50 µm). In the upper right corner for each concentration, the 
fluorescence integrated intensity of the whole well is indicated. 
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The building blocks alone also form supramolecular constructs but have 
a larger size distribution and a higher PDI. Interestingly, variation of the 
molar ratio of the Gd building block to peptide-bearing building block 
did not greatly influence the size. However, Mix-2 had the lowest size 
(95 nm) and the lowest PDI (0.22), which is also the case for Anti-Mix-2. 
Finally, the size range obtained, between 10 and 100 nm, is exactly the 
one needed for prolonged blood circulation [42]. With this mean size, 
the micelles are not prone to massive vascular extravasation and 
excessively fast renal excretion. 
5.2. Building block choice 
Four building blocks were selected for the mixed micelles. Each block 
has a specific role (Table 1) and was carefully chosen to formulate 
target-specific micelles, enabling vascular molecular imaging. 
Gd-DO3A-Tyr-(C18)2 is responsible for MRI contrast; it has a DOTA- 
based ligand loaded with a Gd3+ cation and two lipophilic arms. Gd- 
DOTA chelate has been proven to be more stable than Gd-DTPA in 
several media, with almost no Gd release in vivo [32,43]. Additionally, 
this building block includes two C18 chains, which participate in the 
hydrophobic core of the micelles. 
DSPE-PEG2000-CREKA is responsible for the binding properties. As 
described above, cardiovascular-related diseases, frequently involving 
unstable plaques containing a soft atheromatous core, are a major cause 
of disability and death; therefore, early imaging is the key to the close-up 
monitoring of the evolution and treatment of this cardiovascular disor-
der. Unstable and partially ruptured plaques develop fibrin clots. The 
CREKA pentapeptide was chosen as the targeting moiety since this short 
peptide specifically binds to fibrin clots. Moreover, CREKA-targeted CAs 
have been successfully tested in cancer imaging [18,38,44]. 
DSPE-PEG2000-IR-774 was synthesized and used in this study for the 
orthogonal detection of micelles by fluorescence imaging. This fluores-
cent near-infrared-emitting dye does not influence the micelle structure 
and was first developed in our lab for specific cancer cell internalization. 
It could add multimodality in these micelles for cancer imaging. 
Finally, DSPE-PEG2000 possesses the hydrophobic and hydrophilic 
chains responsible for the micelle core structure. The PEG2000 chains 
provide long blood circulation and stealth properties to micelles, and 
DSPE molecules contribute to the consolidation of the whole structure. 
As discussed above, the lowest PDI was observed in the different 
mixes and not in the building blocks alone, which are assembled as 
molecule aggregates rather than micelles. This was also demonstrated 
by the stability assay (Table 2). 
5.3. Mix characterizations 
The mixed-micelle strategy, using several different building blocks, 
was chosen as the formulation technique to help overcome liver accu-
mulation. Most often, micelles with one building block are very stable, 
and some of them are trapped by the liver for a prolonged period of time, 
which is not a viable approach. On the other side mixed-micelles will 
decompose faster and expectantly will be eliminated with no liver 
accumulation. 
Three mix compositions were chosen (Table 2) to test the influence of 
different building blocks. DSPE-PEG2000 and DSPE-PEG2000-IR-774 had 
their molar fraction fixed, and Gd-DO3A-Tyr-(C18)2 and DSPE-PEG2000- 
CREKA were included at various proportions between 20 % and 50 %. 
For each experiment, the concentration of a specific building block was 
fixed to a value to allow comparison. 
Several characterization assays were performed. The first was the 
cell viability assay. One breast cancer cell line, one healthy breast cell 
line and two vascular cell lines were tested. As shown in Fig. 4, no sig-
nificant cytotoxicity was observed for the mixes and anti-mixes, 
demonstrating the suitability of the mixture of components in the mi-
celles. Interestingly, building blocks DSPE-PEG2000-IR-774 and Gd- 
DO3A-Tyr-(C18)2 were more toxic when tested by themselves but only at 
concentrations that would never be reached in vivo. 
Another important measurement was the relaxivity determination of 
the developed CA. In Fig. 5B, the relaxivity graph shows a curve for the 
three mixes, proving the formation of a nanostructure in solution. 
Moreover, the relaxivity of the micelles was much higher than that of the 
marketed Gd-DOTA. This property is very important with high-field 
magnets, as has already been discussed in our previous works 
[14,15,31]. 
This assay is used in conjunction with MRI phantom imaging and 
signal intensity measurements. In Fig. 5A, no visual difference was 
observed between the mixes, anti-mixes and marketed Gd-DOTA. 
However, in the SI graphs, the intensities for the mixes and anti-mixes 
were slightly higher than those of Gd-DOTA. The concentration of Gd 
in the mixes was precisely measured by ICP-MS; therefore, this differ-
ence is less likely due to the Gd concentration. Consequently, this dif-
ference can be clearly attributed to the difference in relaxivity. 
In short, mixed micelles formulated with sizes ranging from 10 to 
100 nm are suitable for applications where blood circulation and 
vascular targeting rather than diffusion in tissues is desired. They 
showed no toxicity toward different cell lines, particularly vascular cell 
lines. Finally, they have a high relaxivity, which makes them visible on 
MRI even at low concentrations. 
5.4. Binding properties 
The most important assay for these formulations was the binding 
assay. The goal of this work was to formulate a CA with strong binding 
properties to fibrin clots. We wanted to first determine the binding po-
tential and then the best mix composition, as we have several building 
blocks. 
Two orthogonal binding assays on fibrin clots were performed. One 
was a fluorescence detection method, and the other was MRI imaging 
and SI quantification. 
For the fluorescence assay, anti-mixes were used as the nontargeted 
controls, and DSPE-PEG2000-IR-774 was used as the negative control. 
The results are reported in Fig. 6. The mixes resulted in curves proving 
the specific binding with a saturation of binding sites. Mix-2 seems to 
have a higher binding property. The anti-mixes and the dye alone 
resulted in a straight line, demonstrating unspecific binding, which was 
much lower than that of the mixes. Statistically a significant difference 
(p < 0.05) is observed between mixes and anti-mixes at almost at all 
concentrations, and between mixes and the wells before washing start-
ing at c = 1 mM. 
The MRI assay provided corresponding results. Fig. 7A shows that 
mixes remain attached to fibrin clots more than the anti-mixes do. Here, 
the negative control was Gd-DOTA, which was completely washed and 
had no binding affinity at all due to its small size. The SI graph confirms 
the visual analysis. The curve of the mixes was always higher, and the 
anti-mixes gave rise to a straight line. Interestingly, no difference was 
observed between the mixes. Here as well the significant difference is 
statistically proved (p < 0.05) between mixes, anti-mixes and the “wells 
before washing” starting from c = 0.25 mM. 
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Therefore, the binding property was clearly demonstrated with these 
two assays. 
All three mixes were attached to fibrin clots, and Mix-2 seems to have 
better binding properties. Furthermore, nontargeted and negative con-
trols support the conclusion. 
5.5. Internalization properties 
Micelles have been designed to first target fibrin clots for atheroma 
MRI imaging. 
In addition, the fluorescent dye used for orthogonal detection in the 
binding assays was designed in our laboratory to target cancer cells. This 
property was tested for all micelles in an additional cell internalization 
assay to show their potential application in cancer cell detection. The 
fluorescent dye is positively charged (Tables 1 and 2) and therefore 
accumulates preferentially in the mitochondria of cancer cells rather 
than in healthy cells due to the higher mitochondrial membrane po-
tential of cancer cells [45]. The cell internalization of the fluorescent 
micelles was therefore tested in cancer and healthy cell lines by 
measuring the colocalization of the fluorescent dye and a MitoTracker™ 
using confocal imaging. As shown in Fig. 8, the micelles effectively enter 
cancer cells at much lower concentrations (1–10 µM) than they enter 
into the healthy cell line (10–50 µM). Additionally, it seems that Mix-1 
enters the cells better than Anti-Mix-1, since CREKA aids in entering 
cancer cells [46,47]. However, this difference is not obvious, and CREKA 
will attach the CAs to the cancer tumor by targeting the leaking vessels, 
and then DSPE-PEG2000-IR-774 enables cancer cell entry. 
For the three mixes and anti-mixes, internalization was observed at 
10 µM in the 
MCF-7 cancer cells (Sup Info Fig. SI3). In contrast, for MCF-10 
healthy cells, internalization was barely observed at 50 µM (Sup Info 
Fig. SI4). 
The fluorescence quantification graph (Sup Info Fig. SI5) confirms 
the visual result and shows a small difference between the mixes and 
anti-mixes in terms of cancer cell line internalization. This strongly 
suggests that CREKA improves cell internalization. Notably, this differ-
ence was not observed in healthy cells. This is due to the high expression 
of fibronectin in the microenvironment of tumor and especially in high- 
risk metastasis breast tumors. The mortality of breast cancer is mostly 
due to metastases formation in other organs such as lungs [48,49]. 
Therefore, the early diagnosis of high-risk metastases mammary tumors 
is crucial for the success of anticancer treatment. It has been shown that 
the evolution of a tumor into metastases can be detected early at the 
molecular level [50]. In fact, the metastases formation is driven by a 
process called epithelial to mesenchymal transition (EMT) [51,52]. EMT 
is characterized by molecular events such as the upregulation of fibro-
nectin [53–56]. CREKA can be used to target fibronectin highly 
expressed in metastases and improve the survival rate of breast cancer. 
These results show the potential use of our micelles for the detection 
of cancer cells by fluorescence imaging. Multifunctionality in imaging 
fibrin clots, on the one hand, and cancer cells, on the other hand, would 
be a desirable property for a new CA. This additional assay supports this 
possibility; however, additional studies still have to be performed. 
5.6. Comparison to similar CREKA nanoconstructs and perspectives 
Recently, several groups have been working on CREKA-based 
nanostructures [18,28,36,38,39,44,57–59]. The potential of this 
pentapeptide to bind fibrin-fibronectin complexes has been proven and 
tested with several products for different indications [18,28,46,60,61]. 
Groups have developed products for imaging cancer and atheroma with 
promising results. 
Cancer imaging requires a smaller structure, which can rapidly exit 
vessels and rapidly reach the target. Several research groups have re-
ported new molecules attaching several Gd-DOTA rings [28,57]. In 
another study, CREKA was bound to PAMAM dendrimer nanoparticles, 
and they were tested on glioblastomas [44]. They integrated an infrared 
dye to achieve multimodality imaging. A micelle structure similar to 
ours has been developed for imaging atherosclerotic lesions [36]; 
however, the authors used a Gd-DTPA chelate instead of Gd-DO3A and 
did not test cancer cell targeting. 
Our micelles perfectly integrate the family of CREKA structures with 
potential for atheroma and cancer imaging. Size homogeneity and sta-
bility are in hand with future in vivo trials. Nontoxicity and high relax-
ivity are also important characteristics for MRI CAs. Three mixes were 
tested, and Mix-2 seems to have several advantages compared to the 
others, particularly in the fluorescence binding assay. 
5.7. General conclusion 
To summarize, our micelles have high potential as multimodal MRI 
CAs for atheroma and most likely cancer imaging. The building blocks 
are simple to synthesize, and the nanoprecipitation formulation method 
has proven its benefit. Binding assays proved the hypothesis of possible 
targeted molecular imaging. The next step will be in vivo trials on several 
mouse models. 
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